Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (LTRN) leverages artificial intelligence and precision medicine to revolutionize oncology drug development. This news hub provides investors and researchers with timely updates on the company's progress in transforming cancer treatment through biomarker-driven approaches.
Access centralized, reliable information on clinical trial milestones, strategic collaborations, and regulatory developments. Our curated news collection simplifies tracking of AI-powered drug discovery advancements and therapeutic pipeline updates specific to Lantern Pharma's innovative platform.
Discover how machine learning accelerates oncology research while maintaining focus on genetic screening precision. The page serves as an essential resource for understanding the company initiatives shaping personalized cancer therapies.
Bookmark this page for streamlined access to verified announcements and analysis-free updates directly impacting Lantern Pharma's position in biotechnology innovation.
Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer therapy company, has announced its second quarter 2024 operating and financial results webcast scheduled for August 8, 2024, at 4:30 p.m. ET. The company, which utilizes its proprietary RADR® AI and machine learning platform to develop targeted cancer therapies, will discuss Q2 results ending June 30, 2024. CEO Panna Sharma and other management team members will lead the call, providing insights on upcoming milestones, clinical trials, and AI platform developments. Interested parties can register for the webcast through the provided Zoom link, with a replay available on the company's investor relations website post-call.
Lantern Pharma (NASDAQ: LTRN) has achieved a milestone in developing a qRT-PCR-based diagnostic for its drug candidate, LP-184. This diagnostic quantifies PTGR1 RNA in tumor samples, helping identify patients likely to respond to LP-184 across various solid tumors. Successful confirmation of PTGR1 as a important biomarker paves the way for further assay validation and eventual use in later-stage clinical trials. Studies have shown that incorporating biomarkers like PTGR1 can significantly enhance clinical trial success rates. LP-184, aimed at treating malignant gliomas, pancreatic cancer, and ATRT, holds both Orphan Drug and Rare Pediatric Disease designations from the FDA.
Lantern Pharma has received a Certificate of Patent from the Japanese Patent Office (JPO) for its drug candidate LP-284, developed using the company's RADR® AI platform. LP-284, aimed at treating relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas, is currently in a Phase 1 clinical trial. Japan is the third country to issue this patent, following the US in April 2023, with anticipated patents in Europe, China, and other countries. Lantern estimates LP-284 could benefit 40,000 to 80,000 blood cancer patients annually, potentially capturing a $4 billion global market. The drug has also received Orphan Drug Designation from the U.S. FDA for the treatment of high-grade B-cell lymphomas and mantle cell lymphoma.
Lantern Pharma Inc. (NASDAQ: LTRN) released its first-quarter 2024 financial results and operational highlights. The company reported progress in multiple clinical trials, obtaining regulatory allowance for the Harmonic™ clinical trial in Japan and Taiwan, and advancing AI-guided drug candidates LP-184 and LP-284. The global market potential for LP-184 and LP-284 is estimated to exceed $12 billion USD. Additionally, collaborations with Starlight Therapeutics and Oregon Therapeutics aim to streamline drug development strategies and leverage AI technologies. The company is focused on precision oncology and the development of high-impact drug candidates, reflecting a positive outlook for future growth.
Oregon Therapeutics and Lantern Pharma are collaborating to optimize the development of the first-in-class drug candidate XCE853, a potent inhibitor of cancer metabolism. The collaboration involves leveraging AI to refine and expand the positioning of XCE853 in new oncology indications, aiming to uncover biomarkers and define potential combination regimens. Lantern Pharma will have equal IP co-ownership and drug development rights in newly discovered biomarkers and indications for XCE853.
Lantern Pharma (NASDAQ: LTRN) will host a webcast on May 9th, 2024, discussing their first quarter 2024 financial results, upcoming milestones, clinical trials, and developments of their AI platform, RADR®. The webcast will be led by Panna Sharma, President and CEO. Register for the webinar here and access the replay on the investor relations section of the Company's website.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
